ljm716
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01598077)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ljm716
- lm716
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02143622 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2015 | Novartis |
| NCT02167854 | Phase 1 | Jun 16, 2014 | Cornell University, Novartis |
| NCT01911936 | Phase 1 | Sep 1, 2013 | Novartis |
| NCT01822613 | Phase 1 | Jul 26, 2013 | Novartis |
| NCT01602406 | Phase 1 | Sep 21, 2012 | Novartis |
| NCT01598077 | Phase 1 | Jul 1, 2012 | Novartis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 5 | 2 | 2012 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1